Combining Topology and Sequence Design for the Discovery of Potent Antimicrobial Peptide Dendrimers against Multidrug-Resistant Pseudomonas aeruginosa

Multidrug‐resistant opportunistic bacteria, such as Pseudomonas aeruginosa, represent a major public health threat. Antimicrobial peptides (AMPs) and related peptidomimetic systems offer an attractive opportunity to control these pathogens. AMP dendrimers (AMPDs) with high activity against multidrug...

Full description

Saved in:
Bibliographic Details
Published inAngewandte Chemie Vol. 126; no. 47; pp. 13041 - 13045
Main Authors Stach, Michaela, Siriwardena, Thissa N., Köhler, Thilo, van Delden, Christian, Darbre, Tamis, Reymond, Jean-Louis
Format Journal Article
LanguageEnglish
Published Weinheim WILEY-VCH Verlag 17.11.2014
WILEY‐VCH Verlag
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Multidrug‐resistant opportunistic bacteria, such as Pseudomonas aeruginosa, represent a major public health threat. Antimicrobial peptides (AMPs) and related peptidomimetic systems offer an attractive opportunity to control these pathogens. AMP dendrimers (AMPDs) with high activity against multidrug‐resistant clinical isolates of P. aeruginosa and Acinetobacter baumannii were now identified by a systematic survey of the peptide sequences within the branches of a distinct type of third‐generation peptide dendrimers. Combined topology and peptide sequence design as illustrated here represents a new and general strategy to discover new antimicrobial agents to fight multidrug‐resistant bacterial pathogens. Multiresistente Bakterien wie Pseudomonas aeruginosa und Acinetobacter baumannii stellen eine Bedrohung für die öffentliche Gesundheit dar. Das kombinierte Design von Topologie und Aminosäuresequenz führte zu neuen antimikrobiellen Peptid‐Dendrimeren mit hoher Aktivität gegen diese Pathogene, was einen neuen und allgemeinen Ansatz zur Entdeckung antimikrobieller Wirkstoffe darstellt.
Bibliography:This work was supported financially by the University of Bern, the Swiss National Science Foundation, the European Marie Curie Initial Training Network BioChemLig, and Swiss TransMed.
Swiss National Science Foundation
University of Bern
ArticleID:ANGE201409270
Swiss TransMed
istex:0B0331BBB8BDF87D0CD1731E144E95AEF9D3BB90
ark:/67375/WNG-D91VVM6L-M
European Marie Curie Initial Training Network BioChemLig
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0044-8249
1521-3757
DOI:10.1002/ange.201409270